Nuo Therapeutics insider sells 200,000 shares at $1.50

Nuo Therapeutics, Inc. reported an insider transaction by CEO/CFO and director David Jorden.

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. reported an insider transaction by CEO/CFO and director David Jorden. On 11/28/2025, he reported a sale of 200,000 shares of common stock at $1.50 per share, leaving him with 1,946,755 shares beneficially owned directly after the trade. The filing notes that the transaction was executed as a private transaction in connection with a personal real estate transaction and that the shares involved are characterized as “restricted” securities under the Securities Act of 1933.

Insider Trade Summary

Net Seller: 200,000 shares

Net Sell 1 txn

Insider JORDEN DAVID EMERSON

Role CEO/CFO

Sold 200,000 shs ($300K)

Type	Security	Shares	Price	Value
Sale	Common Stock	200,000	$1.50	$300K

Holdings After Transaction: Common Stock — 1,946,755 shares (Direct)

Footnotes (1)

1. F1. The transaction reported herein was made in a private transaction to facilitate a personal real estate transaction whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuo Therapeutics (AURX) report?

Nuo Therapeutics reported that CEO/CFO and director David Jorden sold 200,000 shares of common stock on 11/28/2025 at $1.50 per share.

How many Nuo Therapeutics (AURX) shares does the insider own after the transaction?

Following the reported transaction, David Jorden beneficially owns 1,946,755 shares of Nuo Therapeutics common stock, held directly.

What is the role of the reporting person at Nuo Therapeutics (AURX)?

The reporting person, David Jorden, is both a director and an officer of Nuo Therapeutics, serving as CEO/CFO.

On what date did the Nuo Therapeutics (AURX) insider transaction occur?

The earliest transaction date reported for the insider trade is 11/28/2025.

How was the Nuo Therapeutics (AURX) insider transaction structured?

The filing explains that the transaction was conducted as a private transaction related to a personal real estate transaction and that the shares involved are treated as “restricted” securities under the Securities Act of 1933.

Is the Nuo Therapeutics (AURX) Form 4 filed by one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, namely David Jorden.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/03/2025 - 06:13 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JORDEN DAVID EMERSON

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TX 77054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO/CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/28/2025		S(1)		200,000	D	$1.5	1,946,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported herein was made in a private transaction to facilitate a personal real estate transaction whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended.

	/s/ David Jorden	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.